Children born with hypoxic-ischemic (HI) brain injury account for a significant number of live births wherein no clinical treatment is available. Limited clinical trials of stem cell therapy have been initiated in a number of neurological disorders, but the preclinical evidence of a cell-based therapy for neonatal HI injury remains in its infancy. One major postulated mechanism underlying therapeutic benefits of stem cell therapy involves stimulation of endogenous neurogenesis via transplantation of exogenous stem cells. To this end, transplantation has targeted neurogenic sites, such as the hippocampus, for brain protection and repair. The hippocampus has been shown to secrete growth factors, especially during the postnatal period, suggesting that this brain region presents as highly conducive microenvironment for cell survival. Based on its neurogenic and neurotrophic factor-secreting features, the hippocampus stands as an appealing target for stem cell therapy. Here, we investigated the efficacy of intrahippocampal transplantation of multipotent progenitor cells (MPCs), which are pluripotent progenitor cells with the ability to differentiate into a neuronal lineage. Seven-day-old Sprague-Dawley rats were initially subjected to unilateral HI injury, which involved permanent ligation of the right common carotid artery and subsequent exposure to hypoxic environment. At day 7 after HI injury, animals received stereotaxic hippocampal injections of vehicle or cryopreserved MPCs (thawed just prior to transplantation) derived either from Sprague-Dawley rats (syngeneic) or Fisher rats (allogeneic). All animals were treated with daily immunosuppression throughout the survival period. Behavioral tests were conducted on posttransplantation days 7 and 14 using the elevated body swing test and the rotarod to reveal general and coordinated motor functions. MPC transplanted animals exhibited reduced motor asymmetry and longer time spent on the rotarod than those that received the vehicle infusion. Both syngeneic and allogeneic MPC transplanted injured animals did not significantly differ in their behavioral improvements at both test periods. Immunohistochemical evaluations of graft survival after behavioral testing at day 14 posttransplantation revealed that syngeneic and allogeneic transplanted MPCs survived in the hippocampal region. These results demonstrate for the first time that transplantation of MPCs ameliorated motor deficits associated with HI injury. In view of comparable behavioral recovery produced by syngeneic and allogeneic MPC grafts, allogeneic transplantation poses as a feasible and efficacious cell replacement strategy with direct clinical application. An equally major finding is the observation lending support to the hippocampus as an excellent target brain region for stem cell therapy in treating HI injury.
INTRODUCTION
and rehabilitation, coupled with the lack of therapy, indicate that HI injury represents a current significant unmet medical need. In the US, an estimated 1 in 4000 The incidence and effects of hypoxic-ischemic (HI) brain injury in children are complex, but the number of live births succumbs to ischemic brain injury (14) . Although more than 95% of these infants survive, they ex-patients affected is large by any assessment. The current therapy for HI injury is limited. The number of affected hibit considerable cognitive and motor deficits throughout their lifetime. Neonatal encephalopathy due to all individuals, the costs necessary to facilitate their care causes occurs in 1-6 of every 1000 births. The risk of damaged brain. Indeed, stem cells have been demonstrated to differentiate into neurons (2, 3, 30) . Transplan-intrapartum neonatal asphyxia is estimated at 2.5% of all live births. Out of this large number of infants, a tation of stem cells has been widely employed as an experimental therapeutic approach in a variety of neuro-lesser number experience HI injury significant enough to produce brain injury with motor and cognitive disabil-logical disorders, such as cerebral ischemia (5, 6, 9, 10, 13, 17, 24, 39) , Parkinson's disease (25, 26, 42) , spinal cord ity. Cerebral palsy or chronic, nonprogressive motor disability affects 1-2 per 1000 individuals in the US. injury (16), induced status epileptics (12), dysmyelinated and neurodegenerative disorders (1, 30) , amyotro-About 6% of these patients have acquired their disability through birth injuries related to HI injury. Overall, a phic lateral sclerosis (36) , and other neurological disorders (2, 3, 20) . These studies provide solid evidence of component of these patients with significant injury due to neonatal stroke or HI injury are easily identifiable therapeutic potential of transplanting stem cells in the clinic for patients with neurological disorders. Over the clinically shortly after birth, and therefore the likely focus as an initial patient group for testing the experimen-last decade, clinical trials of cell transplantation have been performed in Parkinson's disease, Huntington's tal therapy in children. Furthermore, if such experimental therapy were successful in this group, the therapy disease, and stroke. Stem cell transplantation therapies have come into fo-might also be suitable for many of the other causes of cerebral palsy or other postischemia indications in the cus as potential treatments for numerous diseases and medical conditions, including HI injury. Experiments brain.
The present study was designed as a proof-of-concept performed by Drs. Verfaillie and Low (21, 22) have demonstrated the broad neuronal lineage potential of experiment. The availability of the grafted cells near or around the site of injury was deemed critical in assessing multipotent progenitor cells (MPCs), which represent an innovative, pluripotent progenitor cell population, iso-the potential therapeutic efficacy of stem/progenitor cells. In order to assure that stem/progenitor cells were accu-lated from the bone marrow of humans, rodents, and primates. MPCs have the ability to differentiate in a con-rately placed at the vicinity of injured site, stereotaxic guided transplantations were performed. Moreover, we trolled manner along multiple developmental lineages upon induction. MPC-derived neurons attained correct considered a transplant target site that was stably injured following HI, but at the same time presented as a favor-neuronal transmitter phenotype and responded appropriately to the neuroanatomical microenvironment (21, 22) . able microenvironment for graft survival. Based on our pilot experiments and reported studies (11, 18, 19) , a dis-In addition, animals that were transplanted with MPCs did not show overt behavioral or physiological alter-crete region of the hippocampus, specifically the CA3 region, was highly vulnerable to HI insult. Accompany-ations, and their brains revealed a normal pathology (21, 22) . These observations indicate feasibility and safety of ing such hippocampal CA3 cell loss was a marked deterioration of behavioral functions, including motor asym-MPCs as a cell source for transplantation therapy. metry and coordination. Accumulating evidence has implicated the hippocampal CA3 region as primarily MATERIALS AND METHODS contributing to these motor abnormalities (29, 33, 34) . In-HI Injury Surgical Procedure terestingly, the neighboring hippocampal region of CA3, namely the dentate gyrus, has been established as a neu-All surgical procedures ( Fig. 1) were conducted under aseptic conditions. Anesthetized (2% isoflurane) ani-rogenic site; however, mere "endogenous neurogenesis" has not been shown sufficient for brain protection and mals were subjected to unilateral, right HI injury. Each litter of Sprague-Dawley rats (Harlan Inc.) was housed repair in ischemic injury models. With the proximity of CA3 to this neurogenic site, it is likely possible that under standard conditions. Offspring were reared with their dams until the time of surgery, and then until wean-brain protection and repair via stem cell therapy could be achieved via synergistic effects of endogenous stem ing at 3 weeks of life. Rat pups underwent permanent ligation of the right common carotid artery at postnatal cells (from the dentate gyrus) and exogenous stem cells (from transplanted stem/progenitor cells). Based on the day 7 (33) . A midline cervical incision was made to expose the right common carotid artery, which was ligated neurogenic and neurotrophic factor-secreting features of the hippocampus, we hypothesized that by targeting this by a single suture. The incision was closed with interrupted 6-0 silk sutures. The pups were then placed with brain area for cell transplantation, attenuation of hippocampal damage, as well as amelioration of motor abnor-the dams for 2 h prior to placement in an 8% oxygen chamber partially immersed in a water bath at 37°C for malities associated with HI injury, could be achieved.
Transplantation of exogenous stem cells, as well as 2.5 h. Animals were then placed on a temperaturecontrolled blanket until they recovered from the anes-stimulation of endogenous stem cells within the injured brain itself, can exert neuroprotection and repair of the thesia. Cell Preparation tests that have been shown to be sensitive assays of behavioral deficits produced by unilateral HI injury. HI The MPCs (provided by Athersys, Inc.) were preinjured rats were tested in elevated body swing test viously characterized by Verfaille and colleagues (22) .
(EBST) and rotarod treadmill test at days 7 and 14 post-Cryopreserved MPCs were thawed at 37°C just prior to transplantation. The EBST provided a motor asymmetry transplantation surgery. Viability was determined using parameter and involved handling the animal by its tail the trypan blue dye exclusion method, and cell concenand recording the direction of the biased body swings. tration and volume for transplantation were adjusted to
We have previously utilized the EBST, and noted that 200,000/3 µl. A minimum of 85% viability postthaw ischemic animals display >75% biased swing activity as was used as a criterion for using the cells for transplantaearly as the day of ischemia surgery (i.e., after recovery tion. The syngeneic cells were harvested from Spraguefrom anesthesia), and such motor asymmetry is stable Dawley rats and prelabeled with green fluorescent profor up to 6 months. Sensorimotor functions were evalutein (GFP), whereas the allogeneic cells were harvested ated using the rotarod treadmill (Accuscan, Inc.). The from Fisher rats and prelabeled with nuclear-targeted exaverage score (total time spent on treadmill divided by pression β-galactosidase gene (β-gal).
five trials) was calculated for each animal on days 7 and 14. Previous studies have shown animals that underwent MPC Intracerebral Injection the ischemic-hypoxia perform significantly worse in this At day 7 postinjury, anesthetized (equithesin 300 mg/ rotarod task up to at least 5 weeks post-HI surgery (19) . kg, IP) animals were fixed in a stereotaxic apparatus (Kopf instruments) and implanted with MPCs directly Immunohistochemical Analyses into the hippocampus (1.2 mm posterior to bregma, 1.5 mm lateral to midline, and 1.8 mm below the dural sur-Following the behavioral testing at 14 days posttransplantation, animals were euthanized (equithesin 500 mg/ face), using a 28-gauge implantation cannula (7, 8) . The predetermined cell dosage (200,000 cells) is within ther-kg, IP) and brains harvested, sectioned at 25 µm thickness using a cryostat (Reichert Jung), and then processed apeutically effective dose range for stem/progenitor cell transplantation in ischemic injury (7, 8) , and refers to for immunohistochemical analyses of graft survival. For brains transplanted with allogeneic β-gal-labeled cells, number of viable cells. Randomly selected animals received syngeneic MPCs (n = 8), allogeneic MPCs (n = free-floating sections were incubated overnight at 4°C with an anti-β-gal antibody (mouse monoclonal, 1:100, 7), or vehicle only (n = 7). Transplantation surgery was carried out within 2 h after thawing the cells. Infusion Promega) with 10% normal horse serum (Vector). After several rinses in PBS, sections were incubated for 1 h rate was 1 µl of cell solution per minute. Following infusion, a 3-min absorption period was allowed before the in Alexa Fluor 488-conjugated goat anti-mouse IgG antibody (1:1000, Molecular Probes), mounted on Super-needle was retracted. A heating pad and a rectal thermometer allowed maintenance of body temperature at frost Plus glass slides (Erie Scientific), and embedded with mounting medium with DAPI (4,6-diamidino-2-about 37°C throughout surgery and following recovery from anesthesia. All animals were treated with daily im-phenylindole; a simple DNA staining of mammalian cells; Vector). For brains transplanted with syngeneic munosuppression (cyclosporin, 1 mg/kg, IP) throughout the survival period.
GFP-labeled cells, 25-µm-thick sections were directly mounted on Superfrost Plus glass slides and embedded Behavioral Testing with mounting medium with DAPI. Epifluorescence microscopy using a FITC filter on sections that were not HI injured rats exhibit deficits in motor functions. Accordingly, we subjected the animals to behavioral processed with GFP antibody allowed reliable detection of GFP-labeled cells and reduced false-positive results. and β-gal-positive cells colabeled with the fluorescent DNA stain DAPI. Allogeneic grafts, detected by anti-β-Brains from vehicle-infused animals were similarly processed with β-gal and GFP epiflouresence as described gal staining and colabeling with DAPI, displayed similar patterns of graft survival in HI injured brains. above. In addition, control studies included exclusion of primary antibody substituted with 10% normal horse se-DISCUSSION rum in PBS. No immunoreactivity was observed in these Therapeutic Equivalence Between Allogeneic controls.
and
Syngeneic MPC Grafts Statistical Analyses
This is the first report demonstrating that transplanta-The behavioral scores were analyzed using repeated tion of syngeneic and allogeneic MPCs produced recovmeasures ANOVA (combining both test periods) and ery from motor deficits associated with HI injury. Allosingle ANOVA (test periods analyzed separately). Post geneic grafts are as efficacious as syngeneic grafts hoc t-tests were performed for pairwise comparisons becharacterized by similar patterns of behavioral recovery tween treatment conditions. The level of significance for both groups of animals transplanted with MPCs. This was set at p < 0.05. therapeutic equivalence between allogeneic and syngeneic grafts indicates that future clinical trials are likely RESULTS to benefit from being able to pool allogeneic MPCs from MPC Grafts Promote Behavioral Recovery healthy individuals in view of the limited therapeutic Repeated measures ANOVA revealed significance in window for ischemic injury. An ample supply of alloge-EBST [F(2, 41) = 8.27, p < 0.001], but not in rotarod neic cells would be a more efficient cell source than tests [F(2, 41) = 2.81, p = 0.07]. Subsequent statistical syngeneic cells, which require labor-extensive proliferaanalyses thus focused on EBST data only. Analyzing the tion techniques. Although we showed here that a 1-week EBST data for each test period using single ANOVA delay of transplantation after HI injury was still effecrevealed significance only at day 14 [F(2, 9) = 6.05, p < tive, the ready availability of allogeneic cells would 0.01], but not at day 7 [F(2, 19) = 2.93, p = 0.08]. At allow immediate transplantation after HI, thereby faciliday 7 posttransplantation, both syngeneic and allogeneic tating rescue of more dying cells at the early stages of MPC transplanted groups of HI injured animals disthe injury. played a trend of less motor asymmetry (64-65% vs.
Targeting the Neurogenic Hippocampus 75%) [not statistically significant; Fisher's Protected for Cell Therapy Least Significant Difference (PLSD): ps > 0.05] com-
The present results revealed that the damaged hippopared to vehicle-infused injured animals ( Fig. 2) . At day campus, specifically the CA3 region, appeared as a suit-14 posttransplantation, MPC transplanted animals exhibable target microenvironment for transplanting MPCs. ited significantly reduced motor asymmetry (66-70%
Recent studies have implicated the injured hippocampus vs. 87%) (Fisher's PLSD: ps < 0.05) than those that refollowing HI as contributing to a number of behavioral ceived the vehicle infusion. Syngeneic and allogeneic alterations including locomotor behavior and rotarod MPC transplanted injured animals did not significantly (29, 33, 34) . Moreover, such HI-induced hippocampal differ in their behavioral improvements at both test peridamage and the resulting motor deficits remain stable ods (Fisher's PLSD: ps > 0.05). As noted above, ANOVA over time (11, 19) . With pyramidal cell-type neurons revealed statistically nonsignificant MPC effects on the comprising the majority of the hippocampal CA3 region, rotarod task. However, a trend of improved motor coordifferentiation of MPCs into this specific neuronal phedination in MPC transplanted injured animals could be notype would probably enhance the repair of this area seen especially at day 14 posttransplantation compared and further improve the recovery of motor functions. Into vehicle-infused injured animals. deed, following transplantation in normal mice, MPCs
MPC Grafts Survive in HI Injured Brains
have been demonstrated to contribute to both pyramidal and granule cell layers of the hippocampus (22) . Be-Immunohistochemical evaluations of graft survival at day 14 posttransplantation revealed that syngeneic and cause it is highly unlikely that the grafted MPCs had differentiated into neurons at this acute 14-day graft allogeneic transplanted MPCs survived in the hippocampal region. Grafted MPCs were detected in the brains of maturation period, the possibility that MPCs secreted trophic factors to rescue the injured, but still viable, host behaviorally recovered HI injured animals as revealed by anti-GFP and anti-β-gal immunostaining (Fig. 3) .
cells seemed as a more plausible alternative mechanism underlying the observed acute behavioral recovery. Con-Both GFP-positive syngeneic grafts and β-gal-positive allogeneic grafts were found mostly in the original hip-versely, transplanted cells might require growth factors to survive. Of note, elevated expression of brain-derived pocampal CA3 transplant site and showed a modest migration towards the adjacent CA2 region. GFP-positive neurotrophic factor (BDNF) in the CA3, CA4, and den- tate gyrus is detected by 2 weeks in the postnatal rat have questioned the "transdifferentiation" potential of stem cells. Recent evidence from our research team re-brain (15). Moreover, an ischemic insult further increases BDNF, especially in the CA3 and dentate gyrus vealed that in cerebral ischemia, survival of stem/progenitor cells may not be that critical for functional re- (28, 40) . Finally, because of the neurogenic feature of the hippocampus, specifically the dentate gyrus, optimal covery as long as the neurotrophic factors secreted by these cells become available in the ischemic brain beneficial effects of stem cell therapy may be realized within the hippocampus via combined endogenous neu- (5, 6, 9) . Our preliminary cell counts (quantitative analyses ongoing) detected only about 1% graft survival for rogenesis and transplantation of exogenous trophic factor-secreting MPCs into the hippocampus. These results, both allogeneic and syngeneic MPCs. Such graft survival is low compared to 5-8% seen routinely in fetal taken together, make the hippocampal region an appealing target for transplantation therapy.
cell grafts in other models of neurological disorders. However, even with such low graft survival, we ob-Mechanisms Underlying MPC Therapeutic Benefits served functional effects of MPC grafts up to 14 days in HI Injury posttransplantation. This would suggest other mechanisms aside from graft survival, such as neurotrophic Controversy exists whether stem/progenitor cell differentiation into neuronal cells is prerequisite for suc-factor secretion by MPCs or possible cell survival, enhancing effects of the MPC grafts on the resident cells. cessful transplantation outcome. Indeed, some studies egy. In the clinic, such stereotaxic operation may pose as a surgical risk to newborns or young children. More-The Need for Adjunct Immunosuppression over, based on recent studies examining cell death in in Cell Therapy transplanted cells, the trauma associated with the stereo-Immunosuppression of the transplant recipients is a taxic surgical procedure and the ongoing disease patholdouble-edged sword in cell transplantation therapy. On ogy could contribute to detrimental inflammatory attack one hand, chronic and high-dose cyclosporin may preto the grafted cells (31, 32, 37, 38) . Indeed, most (85%) of sent with deleterious side effects (4). On the other hand, the grafted cells die within the 48 h posttransplantation cyclosporin may possess neuroprotective properties (4) . (31, 32, 37, 38) . Accordingly, exploring a minimally inva-The present HI injured animals that received vehicle sive method of cell delivery, such as intravenous or inalone but treated with cyclosporin did not display any tracarotid administration, is warranted. detectable behavioral improvements nor exacerbation of
The MPC material that we envision in the clinic is an functional deficits, perhaps due to the delay in timing of off-the-shelf "thaw-and-transplant" stem/progenitor cell drug injection (i.e., 1 week postinjury). In large part due product that would be a convenient donor cell source. to cyclosporine's inability to cross the blood-brain bar-Cryopreserved cells, such as the MPCs used here, circumrier, the drug's neuroprotective effects only become evivent the logistical problems inherent with long-distance dent when administered before, during, or immediately shipment of cells between production facility and transafter the brain insult when the barrier is breached (23, plant centers, thus allowing more flexibility in schedul-41). The present paradigm allowed a 7-day recovery peing the transplant surgery. riod from HI prior to initiating cyclosporin treatment.
Conclusion Although the blood-brain barrier has been demonstrated to remain compromised up to 12 days postinjury (4), the MPC transplantation is a feasible and efficacious cell replacement strategy for neonatal HI injury. The MPC-5-day period (day 7 to day 12) may be too short for cyclosporin to exert any effect. mediated behavioral recovery was more robust in the cells and human neurons derived from a clonal cell line. simple task of body swing motor asymmetry and only 
